Further, the expression of the proliferation marker Ki67 was significantly reduced in tumor samples from all three treatment groups (Figure 6f,g, and Supplementary Figure S4f,g, bottom panel), with the lowest positive percentage and weakest staining strength of the Ki-67 marker in the samples from the combination treatment group (Tam plus Dox). This evidence concerns the gene MKI67 and neoplasm.